The Firm
201-896-4100 info@sh-law.comFirm Insights
Supreme Court Decision on Genetic Patents Shifts Biotech IP Landscape
Author: Scarinci Hollenbeck, LLC
Date: July 3, 2013
The U.S. Supreme Court recently issued a mixed decision on the patentability of human genes.
The justices concluded that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but that cDNA (complimentary DNA) is patent eligible because it is not naturally occurring.

The patents at issue in Association For Molecular Pathology. et al. v. Myriad Genetics, Inc., et al. relate to Myriad’s discovery of the precise location and sequence of the BRCA1 and BRCA2 genes. Mutations in these genes can dramatically increase an individual’s risk of developing breast and ovarian cancer. Myriad had used its DNA patents to claim exclusive rights to isolate an individual’s BRCA1 and BRCA2 genes for testing.
The Court found that Myriad’s DNA claim falls within the law of nature exception to patent eligibility. As explained in the opinion, “Myriad did not create or alter either the genetic information encoded in the BCRA1 and BCRA2 genes or the genetic structure of the DNA. It found an important and useful gene, but groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the §101 inquiry.”
As a natural product, that human DNA cannot be patented was a result obvious to many. While initially celebrated as a victory for civil liberties, scientific freedom, and patients, the implications of the decision are not clear.
The Court also concluded that cDNA is not a “product of nature” and, thus, it is patent eligible. “Its creation results in an exons-only molecule, which is not naturally occurring. Its order of the exons may be dictated by nature, but the lab technician unquestionably creates something new when introns are removed from a DNA sequence to make cDNA.” the Court held.
While the decision at first glance seems to draw a simple, bright line between DNA (not patentable) and cDNA (patent eligible), it may just be the initial stage of the next patent battles, for cDNA is the workhorse in molecular research. However, cDNA is, in a nutshell, a laboratory “copy” (that has the same genetic information as a copied gene) that does not require much effort to create.
As for how the decision will impact patents currently pending before the U.S. Patent and Trademark Office, the agency has already issued preliminary guidance. It states that Myriad significantly changes the Office’s examination policy regarding nucleic acid-related technology. Going forward, the USPTO provides the following guidance to its patent examiners:
As of today, naturally occurring nucleic acids are not patent eligible merely because they have been isolated. Examiners should now reject product claims drawn solely to naturally occurring nucleic acids or fragments thereof, whether isolated or not, as being ineligible subject matter under 35 U.S.C. § 101. Claims clearly limited to non-naturally-occurring nucleic acids, such as a cDNA or a nucleic acid in which the order of the naturally occurring nucleotides has been altered (e.g., a man-made variant sequence), remain eligible. Other claims, including method claims, that involve naturally occurring nucleic acids may give rise to eligibility issues and should be examined under the existing guidance in MPEP 2106, Patent Subject Matter Eligibility.
To be sure, by invalidating the DNA patents, the Court did lift a barrier to innovation, but whether scientific and medical progress is facilitated by the decision remains to be seen, as trade secrets protection of discoveries will likely be emphasized in the future.
If you have any questions about this case or would like to discuss the legal issues involved, please contact me, Kenneth Oh, or the Scarinci Hollenbeck attorney with whom you work.
- Practices: Intellectual Property, Patents
- Locations: New York City, Red Bank, NJ, Little Falls, NJ
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

A Fort Monmouth redevelopment agreement imposes obligations beyond a traditional property purchase, including construction deadlines, financial commitments, permitted uses, and restrictions on future transfers. Fort Monmouth’s ongoing redevelopment presents significant opportunities for real estate developers, investors, and businesses seeking to establish or expand their presence in Monmouth County. However, acquiring and developing property at the […]
Author: Donald M. Pepe

As battery energy storage system (BESS) projects move from planning to construction, developers and property owners must address an issue that extends well beyond zoning approvals and interconnection agreements: what happens when something goes wrong? To avoid unforeseen liability, developers should address fire code compliance, emergency response planning, contractual risk allocation, and environmental liability before […]
Author: Nicholas Wall

Case law following the 2010 amendments to Federal Rule of Civil Procedure 26 offers guidance on how courts are likely to address whether an expert witness’s AI records are subject to discovery. Key Takeaways Rule 26 Expert Discovery After the 2010 Amendments This article addresses the question courts and lawyers have faced in recent cases: […]
Author: Chris Seelinger

“Show how 3M is 0% at fault.” The absurd tale of how a 350-page ChatGPT history for 3M’s expert witness was produced during a deposition is more likely than you think. It’s an inevitable trend, and an unsettled question for federal courts as experts make generative AI part of their workflow. Key Takeaways Expert Witness […]
Author: Chris Seelinger

Screenshots have changed the risks of electronic communications. The screenshot problem is that messages intended for one person or a small group can be copied, forwarded, preserved, and ultimately presented to opposing counsel, regulators, journalists, customers, or a jury. Businesses should recognize that a truly private digital conversation is increasingly unreliable and ensure their policies, […]
Author: Sean M. Pena

Developers, engineering, procurement, and construction (EPC) contractors, and equipment suppliers each play a critical role in completing a BESS project. However, when equipment costs rise, deliveries are delayed, or regulations change, determining who bears the financial consequences can become contentious. Well-drafted project agreements are essential to sound risk allocation. Key Takeaways This article is Part […]
Author: Nicholas Wall
No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.
Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.
Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.
